Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25400231 | 0.94 | RAB9A (0.49) | GAAMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL25403205 | 0.94 | RAB9A (0.49) | GAAMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL25398177 | 0.91 | MAPT (0.48) | MEN1KMT2AS1PR1 | |
| SCHEMBL25400913 | 0.85 | MAPT (0.47) | RAB9AS1PR1 | |
| SCHEMBL26554128 | 0.85 | LMNA (0.46) | GAAMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL25401784 | 0.84 | HDAC6 (0.46) | GAAS1PR1KAT8PPARA | |
| SCHEMBL25404180 | 0.84 | HDAC6 (0.46) | GAAS1PR1KAT8PPARA | |
| SCHEMBL25400399 | 0.84 | HDAC6 (0.46) | GAAS1PR1KAT8PPARA | |
| SCHEMBL25401030 | 0.84 | HDAC6 (0.46) | GAAS1PR1KAT8PPARA | |
| SCHEMBL25402801 | 0.84 | HDAC6 (0.45) | GAAS1PR1KAT8PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331683-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2023-10-19 | — | — | US | disclosed |
| EP-4211111-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | University of Virginia Patent Foundation (US) | 2023-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331683-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | SPNS2, SPCS2, SMN1; SMN2 | GAA 3595/4885MEN1 3339/4885KMT2A 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.